Literature DB >> 9806044

Risk factors for primary Pneumocystis carinii pneumonia in human immunodeficiency virus-infected adolescents and adults in the United States: reassessment of indications for chemoprophylaxis.

J E Kaplan1, D L Hanson, T R Navin, J L Jones.   

Abstract

Risk factors for the development of a first episode of Pneumocystis carinii pneumonia (PCP) were investigated in the Adult and Adolescent Spectrum of Disease Project, a medical record review study involving longitudinal follow-up of human immunodeficiency virus-infected adults in 9 US cities. Risk factors included decreasing CD4 lymphocyte count and history of AIDS-defining illness, non-P. carinii pneumonia, oral thrush, or unexplained fever for > or = 2 days; PCP prophylaxis was protective. PCP incidence/100 person-years of observation among persons not prescribed PCP prophylaxis was higher in those with CD4 lymphocyte counts < 250 cells/microL or CD4 cell percent < 14% (8.3; 95% confidence interval [CI], 7.7-9.0) than in persons with CD4 cell counts < 200 or history of thrush or fever, which constitute current criteria for prophylaxis against PCP (5.9; 95% CI, 5.5-6.4). Because of increased efficiency in capturing persons at highest risk, CD4 cell count < 250 or CD4 cell percent < 14% should be considered as criteria for prophylaxis against first episodes of PCP.

Entities:  

Mesh:

Year:  1998        PMID: 9806044     DOI: 10.1086/515658

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  20 in total

Review 1.  1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. U.S. Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA).

Authors: 
Journal:  Infect Dis Obstet Gynecol       Date:  2000

Review 2.  Prophylaxis of Pneumocystis carinii pneumonia: too much of a good thing?

Authors:  R F Miller
Journal:  Thorax       Date:  2000-08       Impact factor: 9.139

3.  2001 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus.

Authors: 
Journal:  Infect Dis Obstet Gynecol       Date:  2002

Review 4.  Update on opportunistic infections in the era of effective antiretroviral therapy.

Authors:  Brian C Zanoni; Rajesh T Gandhi
Journal:  Infect Dis Clin North Am       Date:  2014-09       Impact factor: 5.982

5.  A two-stage sampling method for clinical surveillance of individuals in care for HIV infection in the United States.

Authors:  Patrick S Sullivan; John M Karon; Faye E Malitz; Stephanie Broyles; Eve D Mokotoff; Susan E Buskin; Patricia L Fleming
Journal:  Public Health Rep       Date:  2005 May-Jun       Impact factor: 2.792

6.  Serologic responses to pneumocystis proteins in HIV patients with and without Pneumocystis jirovecii pneumonia.

Authors:  Matthew R Gingo; Lorrie Lucht; Kieran R Daly; Kpandja Djawe; Frank J Palella; Alison G Abraham; Jay H Bream; Mallory D Witt; Lawrence A Kingsley; Karen A Norris; Peter D Walzer; Alison Morris
Journal:  J Acquir Immune Defic Syndr       Date:  2011-07-01       Impact factor: 3.731

7.  Pneumocystis carinii expresses an active Rtt109 histone acetyltransferase.

Authors:  Theodore J Kottom; Junhong Han; Zhiguo Zhang; Andrew H Limper
Journal:  Am J Respir Cell Mol Biol       Date:  2010-07-23       Impact factor: 6.914

8.  (1-3)-beta-D-glucan in association with lactate dehydrogenase as biomarkers of Pneumocystis pneumonia (PcP) in HIV-infected patients.

Authors:  F Esteves; C-H Lee; B de Sousa; R Badura; M Seringa; C Fernandes; J F Gaspar; F Antunes; O Matos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-02-03       Impact factor: 3.267

9.  Mutations in the Pneumocystis jirovecii DHPS gene confer cross-resistance to sulfa drugs.

Authors:  Peter Iliades; Steven R Meshnick; Ian G Macreadie
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

10.  Characterization of a novel ADAM protease expressed by Pneumocystis carinii.

Authors:  Cassie C Kennedy; Theodore J Kottom; Andrew H Limper
Journal:  Infect Immun       Date:  2009-05-18       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.